Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells $2,269,327.66 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 133,333 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the completion of the transaction, the chief executive officer now directly owns 3,773,802 shares of the company's stock, valued at $64,230,110.04. The trade was a 3.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Christopher Richard Anzalone also recently made the following trade(s):

• On Thursday, January 2nd, Christopher Richard Anzalone sold 11,520 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $19.05, for a total transaction of $219,456.00.
• On Monday, December 23rd, Christopher Richard Anzalone sold 12,563 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $19.59, for a total transaction of $246,109.17.
• On Wednesday, December 18th, Christopher Richard Anzalone sold 26,712 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $21.24, for a total transaction of $567,362.88.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock traded down $0.70 during trading on Friday, reaching $16.97. The company had a trading volume of 1,354,112 shares, compared to its average volume of 1,987,845. The firm's 50-day simple moving average is $19.39 and its 200 day simple moving average is $20.52. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $16.57 and a 1-year high of $35.47. The firm has a market capitalization of $2.14 billion, a PE ratio of -3.28 and a beta of 0.92. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09.

Remove Ads

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). As a group, equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARWR. Mirae Asset Global Investments Co. Ltd. boosted its stake in Arrowhead Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company's stock worth $88,000 after purchasing an additional 788 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Arrowhead Pharmaceuticals by 79.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 14,498 shares of the biotechnology company's stock worth $281,000 after purchasing an additional 6,424 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in Arrowhead Pharmaceuticals by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 14,417 shares of the biotechnology company's stock worth $279,000 after purchasing an additional 980 shares during the last quarter. Privium Fund Management B.V. boosted its stake in Arrowhead Pharmaceuticals by 16.2% during the 3rd quarter. Privium Fund Management B.V. now owns 333,356 shares of the biotechnology company's stock worth $6,457,000 after purchasing an additional 46,420 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth $494,000. Institutional investors and hedge funds own 62.61% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ARWR. B. Riley reissued a "buy" rating and set a $38.00 price target (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Piper Sandler dropped their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 27th. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Citigroup dropped their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating on the stock in a research note on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $41.44.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.